Kexun Zhou

1.2k total citations
39 papers, 734 citations indexed

About

Kexun Zhou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kexun Zhou has authored 39 papers receiving a total of 734 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Kexun Zhou's work include Cancer Immunotherapy and Biomarkers (11 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Lung Cancer Treatments and Mutations (8 papers). Kexun Zhou is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Lung Cancer Treatments and Mutations (8 papers). Kexun Zhou collaborates with scholars based in China and United States. Kexun Zhou's co-authors include Shi H, Yanyan Lou, Rami Manochakian, Ruqin Chen, Qiu Li, Yujie Zhao, Abdel‐Ghani Azzouqa, Yan Zhang, Wei‐Ting Liao and Feng Wen and has published in prestigious journals such as Bioresource Technology, Frontiers in Immunology and Experimental Cell Research.

In The Last Decade

Kexun Zhou

36 papers receiving 728 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kexun Zhou China 14 402 304 208 128 90 39 734
Yoshiko Umeyama Japan 16 490 1.2× 554 1.8× 263 1.3× 146 1.1× 39 0.4× 35 813
K. Nathan Sankar United States 14 269 0.7× 170 0.6× 124 0.6× 80 0.6× 80 0.9× 41 526
Huilin Xu China 14 325 0.8× 174 0.6× 113 0.5× 96 0.8× 67 0.7× 38 515
Delphine Topart France 12 425 1.1× 234 0.8× 122 0.6× 231 1.8× 85 0.9× 29 606
Davorin Radosavljević Serbia 14 665 1.7× 570 1.9× 194 0.9× 106 0.8× 29 0.3× 53 952
Júlio Oliveira Portugal 18 502 1.2× 412 1.4× 283 1.4× 208 1.6× 71 0.8× 41 1.1k
Michael Cecchini United States 12 297 0.7× 161 0.5× 151 0.7× 111 0.9× 66 0.7× 79 601
Dominic Smethurst United Kingdom 10 242 0.6× 105 0.3× 285 1.4× 73 0.6× 88 1.0× 31 550
Fernando C. Santini United States 13 685 1.7× 464 1.5× 211 1.0× 143 1.1× 115 1.3× 34 958
Riccardo Ricotta Italy 13 307 0.8× 192 0.6× 165 0.8× 141 1.1× 37 0.4× 37 511

Countries citing papers authored by Kexun Zhou

Since Specialization
Citations

This map shows the geographic impact of Kexun Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kexun Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kexun Zhou more than expected).

Fields of papers citing papers by Kexun Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kexun Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kexun Zhou. The network helps show where Kexun Zhou may publish in the future.

Co-authorship network of co-authors of Kexun Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Kexun Zhou. A scholar is included among the top collaborators of Kexun Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kexun Zhou. Kexun Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhou, Kexun, et al.. (2025). Cancer vaccines: platforms and current progress. Molecular Biomedicine. 6(1). 3–3. 15 indexed citations
2.
Zhou, Kexun, et al.. (2025). Gut microbiota shapes cancer immunotherapy responses. npj Biofilms and Microbiomes. 11(1). 143–143. 15 indexed citations
3.
Zhou, Kexun, et al.. (2024). Nanoparticles as a Novel Platform for Cardiovascular Disease Diagnosis and Therapy. International Journal of Nanomedicine. Volume 19. 8831–8846. 10 indexed citations
4.
Wen, Feng, et al.. (2024). Promising first‐line immuno‐combination therapies for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis. Cancer Medicine. 13(16). e70094–e70094. 2 indexed citations
5.
Zhou, Kexun, et al.. (2024). Pathogenesis and Systemic Treatment of Hepatocellular Carcinoma: Current Status and Prospects. Molecular Cancer Therapeutics. 24(5). 692–708. 1 indexed citations
6.
7.
Zhou, Kexun, et al.. (2023). Signalling in pancreatic cancer: from pathways to therapy. Journal of drug targeting. 31(10). 1013–1026. 5 indexed citations
8.
Ma, Qizhi, Pei Shu, Kexun Zhou, & Yongsheng Wang. (2023). Case Report: Termination of unplanned pregnancy led to rapid deterioration of non-small-cell lung cancer during osimertinib treatment. Frontiers in Oncology. 13. 1073938–1073938.
9.
Zhou, Kexun, Yingping Liu, & Hong Zhu. (2023). Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review. Frontiers in Oncology. 13. 1254026–1254026. 4 indexed citations
10.
Zhou, Kexun, Xuyu Gu, Ting Yu, et al.. (2022). Identification pyroptosis-related gene signature to predict prognosis and associated regulation axis in colon cancer. Frontiers in Pharmacology. 13. 1004425–1004425. 2 indexed citations
11.
H, Shi, Karan Seegobin, Kexun Zhou, et al.. (2022). Genomic landscape of lung adenocarcinomas in different races. Frontiers in Oncology. 12. 946625–946625. 26 indexed citations
12.
Yu, Ting, Chunhua Liu, Wen Nie, et al.. (2022). Integratively Genomic Analysis Reveals the Prognostic and Immunological Characteristics of Pyroptosis and Ferroptosis in Pancreatic Cancer for Precision Immunotherapy. Frontiers in Cell and Developmental Biology. 10. 826879–826879. 12 indexed citations
13.
Liao, Wei‐Ting, David W. Hutton, Qiuji Wu, et al.. (2021). Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors. Frontiers in Oncology. 11. 692005–692005. 1 indexed citations
14.
Yang, Yang, Liangliang Bai, Wei‐Ting Liao, et al.. (2021). Comprehensive analysis of EMT-related genes and lncRNAs in the prognosis, immunity, and drug treatment of colorectal cancer. Journal of Translational Medicine. 19(1). 391–391. 44 indexed citations
15.
Zhou, Kexun, Shi H, Ruqin Chen, et al.. (2021). Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer. JAMA Network Open. 4(1). e2032276–e2032276. 31 indexed citations
16.
Liao, Wei‐Ting, Jiaxing Huang, Guiqi Zhu, et al.. (2019). S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial. Expert Review of Pharmacoeconomics & Outcomes Research. 20(1). 133–138. 6 indexed citations
17.
Zhou, Kexun, Jing Zhou, Jiaxing Huang, et al.. (2019). Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung Cancer. 130. 1–4. 57 indexed citations
18.
Zhang, Mengxi, Pengfei Zhang, Kexun Zhou, & Qiu Li. (2019). Remarkable Response of Metastatic Gallbladder Carcinoma to Apatinib After Failed Multiline Chemotherapies: A Case Report and Literature Review. Frontiers in Oncology. 9. 1180–1180. 1 indexed citations
19.
Huang, Jiaxing, Wei‐Ting Liao, Jing Zhou, et al.. (2018). Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial. Cancer Management and Research. Volume 10. 4065–4072. 6 indexed citations
20.
Wang, Yongjiang, et al.. (2016). Using thermal balance model to determine optimal reactor volume and insulation material needed in a laboratory-scale composting reactor. Bioresource Technology. 206. 164–172. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshiko Umeyama Breakdown of academic impact, for papers by K. Nathan Sankar Breakdown of academic impact, for papers by Huilin Xu Breakdown of academic impact, for papers by Delphine Topart Breakdown of academic impact, for papers by Davorin Radosavljević Breakdown of academic impact, for papers by Júlio Oliveira Breakdown of academic impact, for papers by Michael Cecchini Breakdown of academic impact, for papers by Dominic Smethurst Breakdown of academic impact, for papers by Fernando C. Santini Breakdown of academic impact, for papers by Riccardo Ricotta
Rankless by CCL
2026